T-CiRA

A joint program between Takeda and Center for iPS Cell Research and Application (CiRA) that will change the future of medicine using iPS cells

Izumo Seigo, Global Head of Regenerative Medicine Unit (Left)
Shinya Yamanaka, Director of Center for iPS Cell Research and Application (CiRA), Kyoto (Right)


Information

T-CiRA research activity will be presented at the booth of Takeda Pharmaceutical Company Ltd. in ISSCR 2018 to be held at Melbourne from 20th-23th June 2018. Please visit our booth and learn more about T-CiRA.

This visual symbolizes the nature of this joint program.
The four colors, red, blue, green and black - applied in the visual symbolize the four defined factors CiRA used when first inducing iPS cells, as well as interaction among patients, researchers, clinicians and iPS cells. The red is not only one of CiRA's image color but is also Takeda's symbol color.

The center of the emblem is a paper crane, which in Japan, represents hopes and prayers for patients. We hope to deliver innovative medicines to patients as quickly as possible. The tri-colored circle surrounding the crane represents T-CiRA striving toward drug discovery through clinical applications of basic research of iPS through diversified projects, as a one team.

Collaborative research aiming to develop innovative treatments over a 10-year period

T-CiRA is a joint research program by the Center for iPS Cell Research and Application (CiRA), Kyoto University and Takeda Pharmaceutical Company Limited. Over a 10-year period and under the direction of CiRA, this joint program will conduct research to develop clinical applications of iPS cells. We aim to develop innovative drugs and cell treatments in such areas as heart failure, diabetes mellitus, neuro-psychiatric disorders, cancer and intractable muscle diseases in order to fulfill the needs of patients promptly.

 

Professor Shinya Yamanaka

Director of Center for iPS Cell Research and Application (CiRA), Kyoto University

"This 10-year joint program with Takeda, Japan's largest pharmaceutical company, will become a powerful engine to realize medical applications using iPS cells," said Yamanaka. "We sincerely thank Takeda's commitment to iPS cell research. This partnership will contribute to the development of new therapies to cure not only major diseases but also rare ones."

Christophe Weber

Representative Director, President & CEO, Takeda

"I am excited that we will be able to collaborate with CiRA, the world's leading institute dedicated to pioneering iPS cell research," said Christophe Weber, President, and Chief Executive Officer of Takeda. "Through this partnership, our company will provide significant assistance over a long period to CiRA's research into iPS cell technology applications, which is a vital part of Japan Revitalization Strategy. It is our hope to deliver innovative treatments that meet patient needs as soon as possible through this collaboration between Takeda and CiRA."


T-CiRA (Takeda-CiRA) Joint Program Framework

Leader: Professor Shinya Yamanaka (Director of CiRA)|Goal: Develop clinical application of induced pluripotent stem (iPS) cells|Areas: Heart failure, diabetes mellitus, neuro-psychiatric disorders, cancer and intractable muscle diseases, etc.

Takeda

  • To provide collaborative funding of 20 billion yen over a 10-year period
  • To provide more than 12 billion yen worth of research support
  • To provide R&D know-how
  • To provide research facilities at Shonan Research Center
  • To provide platform for drug development
  • To provide access to compound libraries
  • To provide researchers

CiRA

  • To direct the research program
  • To provide iPS cell technologies
  • To provide drug development targets and assay systems
  • To provide principle investigators, researchers and postdoctoral fellows

Shonan Health Innovation Park

A global research center, created by merging the Osaka and Tsukuba Research Centers, helps accelerate innovations in drug development. Here, approximately 1,200 researchers conduct non-clinical research from the early stages of the R&D process such as drug targeting and compound candidate selection to placing drugs on the market.

Cutting-edge research towards the clinical application of iPS cells

Center for iPS Cell Research and Application (CiRA) will possibly bring on breakthrough changes to the future of medicine including the research and development of new drugs, cell therapies and drug safety evaluation processes. T-CiRA will conduct cutting-edge research towards the clinical application of iPS cells in areas such as heart failure, diabetes mellitus, neuro-psychiatric disorders, cancer and intractable muscle diseases at Takeda's Shonan Health Innovation Park.

 

Research to be conducted by T-CiRA

We are committed to providing innovative treatments to patients through iPS cell technology.

At T-CiRA, several novel research projects are underway for creating medical applications of iPSC, led by nine principal investigators.

Main Areas of Research

  • Research towards the clinical application of iPS cells for heart failure, diabetes mellitus, neuro-psychiatric disorders, cancer and intractable muscle diseases, etc.
  • Research to develop medicines and cell therapies using iPS cells.

Project Details

Makoto Ikeya (PI)
Daisuke Kamiya (Sub PI from CiRA)
Yayoi Toyooka (Sub PI from CiRA)
Asano Asami (Co PI from Takeda)
Kazumi Take (Sub PI from Takeda)

A new research platform with human iPSC-derived neural crest cells and its applications for drug discovery and regenerative medicine

Neural crest cells differentiate into diverse cell type lineages such as bones and peripheral neurons, suggesting their great potential for clinical applications. Dr. Ikeya’s team aims to create methods to maintain cultures of human iPSC-derived neural crest stem cells and to induce them to differentiate into various types of cells. Moreover, they hope to construct an disease model in combination with related technologies and apply it to drug development and regenerative medicine.

Learn more

 

 

Haruhisa Inoue (PI)
Takeshi Niki (Sub PI from CiRA)
Takeshi Hioki (Sub PI from Takeda)
Makoto Furusawa (Sub PI from Takeda)

ALS drug discovery and development using patient-derived iPSCs

Dr. Inoue’s team conducts research into amyotrophic lateral sclerosis (ALS), a neurodegenerative disease for which there is no effective cure. They aim to develop new therapeutic drugs using patient-derived iPSCs and Takeda's compound libraries.

Learn more

 

 

Shin Kaneko (PI)
Yuta Mishima (Sub PI from CiRA)
Shoichi Iriguchi (Sub PI from CiRA)
Akira Hayashi (Co PI from Takeda)
Yoshiaki Kassai (Co PI from Takeda)

Development of a novel immunotherapy using iPSC-derived cancer antigen-specific T-cells

Dr. Kaneko's team is trying to develop a novel cancer immunotherapy using iPSC-derived immune cells. We aspire to realize "off-the-shelf" allogeneic products for cancer patients by combining CiRA's human iPS cell stock for regenerative medicine with Takeda's experience in drug production.

Learn more

 

 

Hidetoshi Sakurai (PI)
Yuko Kokubu (Sub PI from CiRA)
Tomoya Uchimura (Sub PI from CiRA)
Ryuichi Tozawa (Co PI from Takeda)
Tomoko Nagino (Sub PI from Takeda)
Masahiro Oka (Sub PI from Takeda)

Drug discovery for intractable muscular disease using patient-derived iPSCs

Dr. Sakurai's team will create novel therapeutic drugs for intractable muscular diseases such as muscular dystrophy and investigate muscular disease models. To achieve this goal, they will utilize patient-derived iPSCs as a tool for disease modeling and drug screening.

Learn more

 

 

Tadashi Suzuki (PI)
Hiroto Hirayama (Sub PI from CiRA)
Ryuichi Tozawa (Co-PI from Takeda)
Takayuki Kamei (Sub PI from Takeda)

Development of therapeutic agents for rare hereditary diseases using iPS cells

Dr. Suzuki's team is focusing on a deficiency in the NGLY1 gene that encodes for the de-N-glycosylating enzyme N-glycanase. They will develop innovative therapeutics for NGLY1 deficiency, a rare inherited disease that presently does not have any therapeutic options, through a combination of basic research findings, iPSC technology and a drug discovery platform.

Learn more

 

 

Takanori Takebe (PI)
Masaru Koido (Sub-PI from Yokohama City University)
Tadahiro Shinozawa (Co PI from Takeda)
Yasunori Nio (Sub PI from Takeda)

Miniature liver technology as a platform for research towards pharmaceutical applications

Based on human iPSC-derived miniature liver technology developed at Yokohama City University, Dr. Takebe’s team is developing a innovative system that can reproduce the complex phenomena found within patients’ bodies. This research will create a novel drug discovery system for intractable diseases and a novel predictive platform for expression analysis of rare adverse events unforeseen in traditional drug discovery research.

Learn more

 

 

Taro Toyoda (PI)
Hirokazu Matsumoto (Co PI from Takeda)
Yutaka Tanoue (Sub PI from Takeda)
Ryo Ito (Sub PI from Takeda)

iPS cell technology-based cell therapy for type 1 diabetes

Dr. Toyoda's team is conducting research into cell therapy against type 1 diabetes mellitus involving transplants of iPSC-derived pancreatic cells. Their current research aim is to develop new treatments based on islet transplantation, but without the current limitations of such transplantation.

Learn more

 

 

Akitsu Hotta (PI)
Naoto Inukai (Co PI from Takeda)
Masataka Ifuku (Sub PI from CiRA)
Kumiko Iwabuchi (Sub PI from CiRA)
Eriya Kenjyo (Sub PI from Takeda)
Hiroyuki Hozumi (Sub PI from Takeda)

Therapeutic genome editing for congenital muscular dystrophy

Dr. Hotta’s team aims to correct the causal genetic mutations involved in severe muscular dystrophy using state-of-the-art genome editing and delivery technologies. The team aims to develop proprietary technology that will enable them to create new gene therapies while, at the same time, confirming repair efficiency and safety using patient-derived iPS cells.

Learn more

 

 

Yoshinori Yoshida (PI)
Kenji Miki (Sub PI from CiRA)
Tomoyuki Nishimoto (Co PI from Takeda)
Norihisa Tamura (Sub PI from Takeda)

Development of an iPSC-based drug discovery platform and application to novel therapy for heart failure

Dr. Yoshida's team aims to create iPSC-derived cardiomyocytes suitable for regenerative therapy and drug discovery research using new technologies such as microRNA-switch technology developed at CiRA. With these cardiomyocytes, they aim to develop cell therapies against heart failure alongside next-generation drug discovery platform and new therapeutic drugs.

Learn more


Putting the promise of IPS Cells into Clinical Practice


T-CiRA Brochure

Come and change the future of medicine with us

T-CiRA recruits researchers that will change the future of medicine using iPS cells with us.

Takeda and CiRA will each recruit 50 researchers (100 researchers in total) from around the world to conduct research at Shonan Health Innovation Park.

We are seeking proposals of new research challenges (projects), and principle investigators (Program-Specific faculty of Kyoto University) who will lead the projects to the accomplishment. The principle investigators are desired to form their own research teams with researchers/research assistants who will support the projects, and to start up and drive forward the projects. Please visit the following CiRA webpage for detailed information on the job.

At first, research will be conducted in areas relating to heart failure, diabetes mellitus, neuro-psychiatric disorders cancer and intractable muscle diseases, but as the project progresses, we expect new areas to be added. When the project is progressing at full speed, we plan to work on approximately 10 projects simultaneously.


Advertisement information


For inquiries regarding T-CiRA

Takeda Pharmaceutical Company Limited Shonan Health Innovation Park

Phone: +81(0)466-32-2111
Fax: +81(0)466-29-4405
Email: T_CiRA@takeda.co.jp



Related Pages